GT Biopharma (GTBP) AI Stock Analysis

• Market Cap: $6.57M
• Dividend Yield: N/A
• Average Volume (3M): 3.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.39
• Revenue Growth: N/A
• EPS Growth: 54.62%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.83
• Shares Outstanding: 10,636,135
• 10 Day Avg. Volume: 8,382,031
• 30 Day Avg. Volume: 3,149,544
• PEG Ratio: -0.02
• Price to Book (P/B): -3.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.45
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.72
• 1Y Price Target: $8.00
• Price Target Upside: 995.89% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 34 Underperform
• Price Target: ―

GT Biopharma's overall stock score reflects significant financial challenges, including a lack of revenue and continuous losses, which are compounded by negative equity and reliance on external financing. While technical indicators are neutral, the valuation metrics highlight the absence of earnings and dividends. These factors, combined with a lack of any notable earnings call or corporate events, result in a low overall score.

GT Biopharma Business Overview & Revenue Model

Company Description

GT Biopharma, Inc. (GTBP) is a clinical-stage biopharmaceutical company focused on developing innovative therapies based on its proprietary TriKE (Tri-specific Killer Engager) platform. Operating in the biotechnology and pharmaceuticals sector, the company is dedicated to the discovery and development of immuno-oncology products designed to harness and enhance the body's natural immune system to target and destroy cancer cells. GT Biopharma's core product candidates aim to address various hematologic malignancies and solid tumors, offering a novel approach to cancer treatment.

How the Company Makes Money

GT Biopharma makes money primarily through the development and commercialization of its proprietary TriKE platform, which is designed to create targeted cancer therapies. The company generates revenue through partnerships, licensing agreements, and potential future sales of its product candidates upon regulatory approval. Key revenue streams include milestone payments, royalties on sales, and collaboration agreements with larger pharmaceutical companies. Additionally, GT Biopharma may receive funding from government grants and research collaborations to support its clinical trials and research initiatives.

GT Biopharma Financial Statement Overview

Summary

GT Biopharma's financial position is precarious, with zero revenue and continuous losses indicating an urgent need for product development or strategic partnerships. The negative equity and reliance on financing highlight financial vulnerabilities, while the persistent cash outflows from operations necessitate a focus on achieving operational efficiencies or securing further investment.

Income Statement

GT Biopharma has consistently reported zero revenue over the years, indicating a lack of commercialized products. The company faces substantial operating losses, as evidenced by the negative EBIT and net income figures across all periods. This lack of revenue growth and persistent losses are significant concerns for the company's financial health.

Balance Sheet

The company has a negative stockholders' equity in recent years, indicating more liabilities than assets, which is a critical warning sign. However, the absence of debt in the latest period reduces financial risk. The low asset base and negative equity position suggest financial instability and potential solvency issues.

Cash Flow

GT Biopharma's operating cash flow has been consistently negative, reflecting ongoing cash burn without incoming revenue. However, the company has managed to maintain liquidity through financing activities, as seen in positive cash flow from financing. The inability to generate free cash flow further underscores the company's dependence on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-9.10M	-13.16M	5.98M	-20.96M	-57.48M	-24.97M
Net Income	-9.10M	-13.16M	-7.60M	-20.88M	-58.01M	-28.30M
Balance Sheet
Total Assets	4.32M	4.23M	14.11M	16.74M	32.17M	5.66M
Cash, Cash Equivalents and Short-Term Investments	2.62M	3.95M	13.97M	16.51M	31.98M	5.30M
Total Debt	0.00	0.00	58.00K	174.00K	31.00K	26.33M
Total Liabilities	1.32M	5.90M	6.63M	5.00M	10.26M	35.09M
Stockholders Equity	3.00M	-1.67M	7.48M	11.73M	21.91M	-29.26M
Cash Flow
Free Cash Flow	-11.36M	-12.90M	-8.85M	-15.22M	-15.61M	-7.26M
Operating Cash Flow	-11.36M	-12.90M	-8.85M	-15.22M	-15.61M	-7.26M
Investing Cash Flow	1.00K	12.89M	-2.01M	12.14M	-23.04M	0.00
Financing Cash Flow	7.47M	2.98M	6.27M	-224.00K	42.32M	12.53M

GT Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.73
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GTBP, the sentiment is Positive. The current price of 0.73 is above the 20-day moving average (MA) of 0.67, above the 50-day MA of 0.71, and below the 200-day MA of 1.82, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.80 is Neutral, neither overbought nor oversold. The STOCH value of 21.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GTBP.

GT Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TOVX	45 Neutral	$10.03M	-0.02	-166.96%	―	―	83.25%
AZTR	38 Underperform	$2.54M	-0.08	-215.04%	―	-100.00%	93.82%
GTBP	34 Underperform	$6.57M	-0.15	-356.99%	―	―	54.62%
REVB	28 Underperform	$2.57M	-0.02	-118.88%	―	―	96.26%
DRMA	15 Underperform	$2.09M	-0.08	-203.36%	―	―	90.53%